HOME >> BIOLOGY >> NEWS
Commercialization deal boosts hope for new sickle-cell drug

A novel once-a-day treatment for sickle-cell disease, based on technology developed at Children's Hospital Boston (CHB) and Beth Israel Deaconess Medical Center (BIDMC), has taken an important step toward the clinic. McNeil Consumer & Specialty Pharmaceuticals and Icagen, Inc., a private biotechnology company, have agreed to jointly develop and commercialize the drug, known as ICA-17043. The agreement follows successful Phase II clinical trials in 90 adults with sickle-cell disease. The companies will collaborate on multicenter Phase III trials, the final step before seeking marketing approval from the U.S. Food and Drug Administration.

Current treatment options are few for sickle-cell disease, a genetic blood disorder that affects millions of children and adults worldwide, including about 70,000 Americans, primarily people of African descent (about 8 percent of African-Americans are carriers). The only approved sickle-cell treatment, developed at CHB 20 years ago, is hydroxyurea. Companies have been slow to invest in additional sickle-cell treatments because the potential market is relatively small. The FDA granted ICA-17043 Orphan Drug Designation in 2000 and Fast Track Status in 2002.

ICA-17043 is related to clotrimazole, an antifungal drug approved in 1975 and long used to treat vaginal yeast infections, jock itch, and athlete's foot. A team led by Dr. Carlo Brugnara, director of the Hematology Laboratory at CHB, discovered in the early 1990s that clotrimazole also reduces sickling of red blood cells.

In sickle cell disease, the body produces an abnormal form of hemoglobin, the compound in red blood cells that carries oxygen. The hemoglobin clumps up and polymerizes forms long rod shapes. This polymerization bends the red cells into sickle-shaped structures, and also causes the cell to lose water. This dehydration, in turn, hardens the cells and promotes sickling by hastening polymerization.

"When
'"/>

Contact: Mary-Ellen Shay
mary.shay@childrens.harvard.edu
617-355-6420
Children's Hospital Boston
3-Aug-2004


Page: 1 2 3

Related biology news :

1. EC boosts European electron microscopy research
2. Bioreactor boosts chemical fermentation by 50 percent: study
3. New genomics tool boosts diabetes research
4. DHEA boosts growth rate of human neural stem cells
5. Marine scientists discover nutrient pollution boosts fungi, bacteria killing Caribbean reefs
6. Sleep boosts ability to learn language, University of Chicago researchers find
7. $13 million grant boosts breast cancer research
8. New national studies show combined hormone replacement therapy boosts stroke, dementia
9. Green tea boosts antimicrobial properties of toothpaste
10. Study boosts confidence in potential screening tool for Alzheimers disease
11. Twenty years of monkey research boosts AIDS knowledge

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Commercialization deal boosts hope for new sickle cell drug

(Date:6/23/2015)...   Valencell, a leader in performance ... recent study that illustrates its PerformTek biometric technology ... In a study conducted at Valencell,s Biometric Lab, ... Apple Watch against a chest strap – the ... The study demonstrated that Valencell,s biometric technology delivers ...
(Date:6/18/2015)... 2015 This report analyzes the worldwide markets ... Product Segments, which includes Immunoassay Analyzers and Reagents: Enzyme ... Immunoassay Systems, and Nephelometric Immunoassay Systems. The report provides ... , Japan , ... Latin America , and Rest of World. ...
(Date:6/17/2015)... HILDEN , Deutschland und GERMANTOWN, Maryland ... Investigator ®   Produktlinie mit ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime ... neue STR-Testkits der Produktlinie Investigator ... DNA-Spuren in den Markt eingeführt. Die neuen Kits zur ...
Breaking Biology News(10 mins):Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3Global Immunoassay Systems Market 2Global Immunoassay Systems Market 3Global Immunoassay Systems Market 4Global Immunoassay Systems Market 5Global Immunoassay Systems Market 6Global Immunoassay Systems Market 7Global Immunoassay Systems Market 8Global Immunoassay Systems Market 9Global Immunoassay Systems Market 10Global Immunoassay Systems Market 11Global Immunoassay Systems Market 12Global Immunoassay Systems Market 13Global Immunoassay Systems Market 14Global Immunoassay Systems Market 15Global Immunoassay Systems Market 16Global Immunoassay Systems Market 17Global Immunoassay Systems Market 18Global Immunoassay Systems Market 19Global Immunoassay Systems Market 20Global Immunoassay Systems Market 21Global Immunoassay Systems Market 22Global Immunoassay Systems Market 23Global Immunoassay Systems Market 24Global Immunoassay Systems Market 25Global Immunoassay Systems Market 26Global Immunoassay Systems Market 27Global Immunoassay Systems Market 28Global Immunoassay Systems Market 29QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6
(Date:7/2/2015)... ... , ... Cuvettes have been used in countless labs for decades. In the past, people ... As expected, this was a daunting and tiring process looking at endless data tables ... able to navigate the complex catalog structure. , Now thanks to FireflySci, scientists are throwing ...
(Date:7/2/2015)... ... July 02, 2015 , ... In’Tech Medical ... instruments in Orthopedics, announced today the acquisition of Turner Medical, Inc ., ... of surgical instruments to the Spine Industry. The acquisition of Turner Medical ideally ...
(Date:7/1/2015)... India , July 1, 2015  Strand Life ... generation sequencing technology to empower cancer care, today announced ... chief executive officer. In his expanded role as now ... strategy, business expansion and worldwide operations effective immediately.  Dr. ... chairman and CEO since its founding in 2000, will ...
(Date:7/1/2015)... , July 1, 2015 InferMed ... technology will ... evidence-based clinical s olutions suite   ... and medical information products and services, announced today the acquisition ... decision support (CDS) technology company. InferMed,s Arezzo technology ...
Breaking Biology Technology:New Cuvette E-Commerce Website Launched by FireflySci 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4
Cached News: